Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.72 |
| ▸ | PHGDH | O43175 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MLYCD | O95822 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964773 | 0.93 | TSHR (0.79) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL10720943 | 0.92 | PHGDH (0.81) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL28296651 | 0.86 | HPGD (0.86) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL946143 | 0.86 | HPGD (0.86) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL9133746 | 0.86 | ALDH1A1 (0.64) | HPGDTSHRALDH1A1SMN1; SMN2MAPK1 | |
| Ammonia Solution, Strong SCHEMBL6028542 | 0.85 | HPGD (0.83) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL2199279 | 0.85 | PHGDH (0.71) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL30449295 | 0.85 | HPGD (0.83) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL27045664 | 0.84 | HPGD (1.00) | HPGDPHGDHTSHRAKR1C3ALDH1A1 | |
| SCHEMBL8150805 | 0.84 | HPGD (0.76) | HPGDPHGDHTSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684775-B1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-11-20 | — | — | EP | claimed |
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | claimed |
| CN-110099905-A | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| CN-1149877-A | Novel elastase inhibitors | HOECHST MARION ROUSSEL INC (US) | 1997-05-14 | — | — | CN | disclosed |
| CN-1149876-A | Perfluoroalkyl ketone inhibitors of elastase and methods of making the same | MERRELL PHARMA INC (US) | 1997-05-14 | — | — | CN | disclosed |
| EP-0763055-A1 | PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0762887-A1 | ACYLATED ENOL DERIVATIVES AS PRODRUGS OF ELASTASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995033762-A1 | PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995033478-A1 | ACYLATED ENOL DERIVATIVES AS PRODRUGS OF ELASTASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | HPGD 1064/4885PHGDH 3308/4885TSHR 2040/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | HPGD 1064/4885PHGDH 3308/4885TSHR 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.